Evidence map›Paper›PMID 42224189›Full record

ArticlePloS one2026

FGFR2 and favorable survival outcomes in resected poorly cohesive cell gastric cancer: Analysis from FGFR2 protein overexpression and genetic variation.

Yun Ji Lee, Inuk Jung, Jin Ho Baek, Jong Gwang Kim, Ki Bum Park, Ji Yeon Park, Oh Kyoung Kwon, An Na Seo, Moonsik Kim, Byung Woog Kang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yun Ji LeeDepartment of Hematology/Oncology, Yeungnam University College of Medicine‌‌, Daegu, Republic of Korea.ORCID https://orcid.org/0000-0002-4186-4636
Inuk JungSchool of Computer Science and Engineering, Kyungpook National University, Buk-gu, Daegu, Republic of Korea.
Jin Ho BaekDepartment of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Kyungpook National University Cancer Research Institute, Daegu, Republic of Korea.
Jong Gwang KimDepartment of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Kyungpook National University Cancer Research Institute, Daegu, Republic of Korea.
Ki Bum ParkDepartment of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Ji Yeon ParkDepartment of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Oh Kyoung KwonDepartment of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
An Na SeoDepartment of Pathology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Moonsik KimDepartment of Pathology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Byung Woog KangDepartment of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Kyungpook National University Cancer Research Institute, Daegu, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePoorly cohesive cell gastric cancer has aggressive and heterogeneous characteristics. This study investigated the clinical significance of fibroblast growth factor receptor 2 expression and genetic variations in patients with PCC-GC. MATERIALS AND

methodsWe retrospectively collected 209 surgically resected stage II and III PCC-GC cases. After FGFR2 immunostaining, we analyzed clinical data and performed targeted sequencing to assess their impact on patient survival.

resultsAmong 209 patients, 89 (42.6%) were classified as stage II and 120 (57.4%) as stage III. FGFR2 overexpression varied by stage, with FGFR2 positivity observed in 61.5% of stage II cases, while FGFR2-negative cases were predominant in stage III patients (60.1%) (P = 0.037). Moreover, lymph node involvement was associated with FGFR2 expression (P = 0.009). FGFR2 positivity significantly correlated with improved disease-free survival (DFS) and overall survival and remained an independent favorable prognostic factor for DFS in multivariate analysis (P = 0.022). Targeted next-generation sequencing was performed in five selected cases, FGFR2 amplification or pathogenic alterations were not found.

conclusionThis study shows that FGFR2 expression was independently associated with improved DFS in PCC-GC. These findings suggest that FGFR2 may serve as a prognostic biomarker in patients with PCC-GC.

Indexed as

GastrectomyGene Expression Regulation, NeoplasticGenetic VariationReceptor, Fibroblast Growth Factor, Type 2Stomach NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID42224189
PMCPMC13225409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.